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Background: Randomised clinical trials (RCTs) involve procedures such as randomisation, blinding, and placebo use,
which are not part of standard medical care. Patients asked to participate in RCTs often experience difficulties in
understanding the meaning of these and their justification.
Methods: We reviewed RCT protocols, statements of the principal investigator (PI), and participant-information
materials, as submitted for opinion to a research ethics committee. We evaluated how the justification for the use
of placebo was described in these documents and how the participants had been informed about randomisation,
placebo use, and the possible risks of receiving placebo.
Results: In total, 52 RCTs were identified. Eighteen of the study protocols (35%) provided some rationale for the
use of placebo. In 15 (29%) of the statements, the PI had provided justification for its use. Possible risks related to
placebo use were described in nine (17%) of the statements. An explanation as to why placebo was necessary
featured in only 12 (23%) of the sets of participant-information materials, and only six (12%) of the documents
discussed the possible risks associated with placebo.
Conclusions: The justification of placebo control was inadequately described in the RCT study protocols, by principal
or national co-ordinating investigators, and in participant-information documents. Furthermore, possible health-related
risks associated with the use of placebo were poorly explained in the participant-information documents. Ethics
committes and study participants need to be better informed of the rationale for the use of placebo, along
with the associated risks.
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Randomised clinical trials (RCTs) are the gold standard
in the demonstration of efficacy and safety of new medical
treatments. These trials involve certain procedures – such
as randomisation, blinding, and the use of placebo – that
are not part of standard medical care. Patients asked to
participate in RCTs often have difficulties in understand-
ing the meaning of these concepts and the justification for
the procedures [1-4].* Correspondence: tapani.keranen@thl.fi
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unless otherwise stated.The ethics of placebo-controlled trials continue to be
subject to heated debate [5,6]. It is agreed that the use of
placebo is acceptable when there is no proven interven-
tion for the condition under study [6,7]. In contrast,
there is disagreement about whether placebo-controlled
trials are ethically justifiable when effective treatment
is available for the disorder in question [5,8]. Placebo
control may be permissible also in connection with
disorders that already have a known effective treatment,
when there are compelling and scientifically sound
methodological reasons for its use and the participants
in the study will not face additional risks of serious or
irreversible harm from exposure to placebo [6,7]. How-
ever, as Millum and Grady [6] point out, that placebol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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not be sufficient to justify its use.
It is important that patients recruited to RCTs under-
stand the study methodology, the interventions to be
used, and their benefits and risks. At present, little is
known about how participants are informed of the pla-
cebo and its effects [9]. A key aim of the study described
here were to evaluate how well the justification for the
use of placebo had been described in the RCT protocols
and by the principal/national co-ordinating investigators.
Another aim was to determine the extent to which the
participants had been informed about randomisation,
placebo use, and any possible risks associated with
placebo treatment. The analysis was based on review of
study protocols, statements of the national and principal
investigators (PIs), and information documents provided
to the participants.
Methods
We surveyed the records of the Research Ethics Com-
mittee of the North Savo Hospital District for 1 January
2006 to 31 December 2012 to identify all applications
for randomised placebo-controlled clinical drug trials.
This body is a local research ethics committee (REC)
assessing study plans that encompass medical research
on humans within the catchment area of the Kuopio
University Hospital and, from October 2010, also the
regions of the North Carelia Central Hospital, Mikkeli
Central Hospital, and Savonlinna Central Hospital. A
clinical trial was defined as a prospective study with
human subjects that is intended to assess the efficacy,
safety, or pharmacokinetics (absorption, distribution,
metabolism, and excretion) of one or more medicinal
products. Both industry-sponsored and investigator-
initiated studies were included. Access to the files of the
ethics committee was granted by the research director of
the North Savo Hospital District.
Data collection and analysis
Data were manually collected by two of the authors, but
the entire multidisciplinary research group discussed
and evaluated the studies selected. After identification
of applicable studies, two of the authors, each independ-
ently, reviewed the protocols and their amendments, the
ethics statements of the principal/national co-ordinating
investigator, and participant-information documents. Ac-
cording to the national guidelines issued by the Finnish
Medicines Agency [10] and the National Medical Research
Ethics Committee [11], the principal or co-ordinating
investigator for a clinical trial must deliver a statement
on the ethical aspects of his or her study, which must
address issues such as assessment of the rationale for
the study, the risk/benefit ratio, and how informed
consent is to be obtained.Two of the authors recorded how the use of placebo
had been justified in the study protocols, in the state-
ment of the principal/national co-ordinating investigator,
and in the participant-information documents. Further-
more, we searched for information in the statements of
the co-ordinating investigators and in the participant-
information documents about the following topics:
randomisation, definition of ‘placebo’, and assessment
of possible risks associated with the use of placebo.
Data were analysed by means of qualitative and quan-
titative content analysis in accordance with the research
objectives via classification and grouping of quotes from
the statements. The data were read through several
times, with an overview created of the content. Mean-
ingful combinations of words and sentences were ex-
tracted, condensed, and coded. After this, codes were
grouped into two main categories: 1) justification for
the use of placebo and 2) blinding and randomisation
as described in the patient-information documents
[12]. The entire analysis process was completed by
two of the authors, independently. These two authors
then discussed the findings, to reach agreement as to
their opinions. After this, the findings were discussed
by the whole research group, for unanimity and veri-
fied validity.
Also, quotes characterising the statements and the in-
formation were gathered and presented to illustrate the
information provided to the ethics committee and to the
people being asked to participate in the trials. Minor
changes to the wording of the quotes were made for
purposes of maintaining confidentiality.
Results
Description of the trials
In all, 52 RCTs were identified, mostly Phase III
international multi-centre trials. The characteristics of
the trials are presented in Table 1. The category ‘Others’
included disorders such as arthritis, osteoporosis, cardio-
vascular diseases, and sepsis.
In 42 of the trials, placebo was to be used in relation
to disorders for which a standard therapy was available,
and in nearly all of those cases (41 studies), standard
therapy was expected to continue during the trial. Eleven
of the 52 trials were connected with disorders for which
there was no standard therapy available. Seven of the
trials involved vulnerable populations – e.g., children or
subjects with dementia.
Justification for the use of placebo
Eighteen of the study protocols (35%) stated a rationale
for the use of placebo. In most of these cases (12 proto-
cols), the scientific rationale was presented as the justifi-
cation, and six protocols cited regulatory guidelines as
the reason for the use of placebo.
Table 1 Characteristics of the 52 randomised
placebo-controlled clinical trials
N (%)





International multi-centre trial 46 (88)
Investigator-initiated national study 6 (12)
Target condition of the trial
Depression 12 (23)
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cipal/national co-ordinating investigator was available
for evaluation. Fifteen (29%) of the PI statements pre-
sented some rationale for the use of placebo, and in all
of these cases, scientific ends – i.e., confirming the effi-
cacy of the study drug or a high placebo response rate
for the disorder under study – were cited as the justifi-
cation (e.g., ‘Placebo is used to scientifically confirm the
efficacy of the study drug’). The investigators also ex-
plained that the use of placebo was acceptable because
the participants would continue to receive the best avail-
able treatment during the trial. Possible risks related to
placebo use were commented upon in nine (17%) of the
statements. In all but one case, the investigator stated
that there were no special risks associated with placebo.
The justification for placebo use was presented in only
12 (23%) of the participant-information documents.
These represent the most frequently occurring phras-
ings: ‘Placebo is used in order to objectively assess the
effects of study treatments’ and ‘The use of placebo as
the comparator is justified because the subjects are
already on the best available treatment’. None of the in-
formation documents provided any data on possible
beneficial effects of placebo. Six (12%) of the information
documents discussed possible risks associated with pla-
cebo by mentioning that the condition of the partici-
pants probably would not change, another stated that
symptoms might worsen or remain unchanged. In addition,
adverse effects of placebo were described as being compar-
able with the situation wherein no drug treatment is given.The meaning of the term ‘placebo’ was explained in 36
(69%) sets of patient-information documents thus: ‘The
placebo looks identical to the active study drugs but
does not include any effective ingredients’. In all, 40
(77%) of the patient-information documents described
the probability of receiving placebo via a statement that
the subjects will have a 50% chance of receiving the
study drug and a 50% chance of getting the placebo,
while one statement explained: ‘The odds of receiving
the placebo are one to three’.
Blinding and randomisation as described in the
patient-information documents
All sets of participant-information documents declared
that the study had a double-blind design, described most
often in the following manner: ‘This is a double-blind
study, which means that neither you nor the study phys-
ician will know which of the study treatments you will
receive’. Information related to possible emergency situ-
ations was given thus: ‘You, your doctor, and the study
personnel will not be told which of the study drugs you
will receive. However, in the event of an emergency,
your doctor will be able to obtain the information on
your treatment if this is necessary for your care’.
In total, 46 information documents (88%) described
what the randomisation procedure meant in practice.
The most common characterisation of randomisation
was this: ‘As if by flipping a coin, a computer-based lot-
tery or otherwise by chance’. However, in none of the
cases was any justification for this procedure provided.
Discussion
We analysed a sample of clinical trial protocols, ethics
statements of principal/national co-ordinating investiga-
tors, and participant-information documents to assess
how the use of randomisation and placebo had been jus-
tified and how possible risks associated with placebo use
had been described. The main finding of our study is
that all of these documents seem to overlook the infor-
mation needs of the various stakeholders in clinical tri-
als, especially those of the trial participants.
The main goal of clinical trial protocols is to present
the aims, methods, and procedures of a scientific trial to
investigators as well as to regulatory authorities. How-
ever, also RECs and funding agencies need to be able to
assess the key trial elements, and they may not always
have sufficient expertise to assess the adequacy of the
study methodology. Therefore, study protocols should
provide explicit justification for the choice of methods,
such as the decision to use placebo control [8]. Only
35% of the protocols that we analysed presented any
justification for the use of placebo, and regulatory
requirements were stated to be the reason in most cases.
According to the European Medicines Agency (EMA),
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clinical trials are to demonstrate superiority to placebo
and to demonstrate non-inferiority or equivalence to an
active control [13]. However, the agency’s guidelines
recognise that a placebo control may sometimes not be
suitable to address all study hypotheses. Therefore, for
evaluation of a trial’s ethics, the protocol should discuss
the feasibility and ethical acceptability of the use of
placebo.
There are limited and partly contradictory published
data on investigators’ attitudes and opinions on how
participants should be informed about trials. In a survey
of oncologists, the investigators considered it to be very
important that participants understand the nature of
trials, alongside the role of randomisation and placebos
[14]. In another study, most of the investigators were
confident that they had given enough information to
their patients, and they expressed the belief that patients
generally comprehend the implications of participation
[15]. On the other hand, a study with 170 breast-cancer
specialists found that only 12% of the physicians deemed
the patients able to understand the information they
needed in order to give informed consent. Hereu et al.
[16] reported that a sample of investigators considered
treatment allocation and the use of placebo among the
least important elements in informing patients of clinical
trials. The statements of principal/national co-ordinating
investigators analysed in our study provided some justifi-
cation for the use of placebo in only about a third of the
cases, and under 20% of the statements discussed any
possible risks related to placebo. The statements may
not, however, reflect the attitudes of the investigators to-
ward informing patients so much as those toward the
REC. There are studies reporting that investigators do
have concerns about patients’ best interests and possible
study-related harm [17,18].
It has been claimed that, while many clinical trial par-
ticipants are satisfied with the information they have re-
ceived and report that they understand the trial design, a
substantial proportion of the subjects have poor or only
partial comprehension of the goals and methods of a
trial [16,19-22]. The concept of randomisation seems to
remain difficult to conceptualise [1-4]. Furthermore,
some who understand what randomisation means have
been found to be reluctant to accept its use [4], though
this finding has not been confirmed in other studies
[23,24]. In our sample of studies, most of the participant-
information documents described randomisation with brief,
simple wording that has been found to be comprehensible
to patients [25]. However, none of the participant-
information documents provided any explanation as
to why the randomisation procedure was necessary.
Because patients tend to think that treatment alloca-
tion should be determined by clinical and personalcharacteristics [2], lack of any explanation for the use
of randomisation may lead to confusion and even re-
fusal to participate. On the other hand, if patients are
not informed that clinical equipoise between the treat-
ments compared in a trial is a fundamental requisite,
they may think that randomisation is a lottery [3].
The probability of receiving one of the treatments
(including placebo) was stated in about 70% of the cases
we examined. Whilst in the survey of Bishop et al. [9],
the chances of receiving a placebo were reported upon
in all the information documents, the people being asked
to participate in nearly one third of our cases were not
able to make a truly informed decision on participation,
on account of lack of knowledge of the probability of
receiving active vs. placebo treatment. They were also
unable to understand the possible benefits and harm
associated with the study fully.
Those asked to participate in the trials were clearly in-
formed of the possibility of receiving a placebo. The pla-
cebo treatment was described as a product that looks
similar to the active study drug but is pharmacologically
inert. This is consistent with Bishop et al’.s findings. In
a large majority (77%) of the participant-information
documents, no rationale for the use of placebo was pre-
sented. This is in quite striking contrast to the findings
of Bishop and colleagues [9], who found an explanation
for the use of placebo in 78% of the participant-
information documents they analysed. The difference
may be due to variations among national guidelines for
providing participant information and to the diversity of
funding sources and trial types. In a parallel with the
findings of Bishop et al. [9], scientific reasons were given
as the justification for the use of placebo in many infor-
mation documents evaluated in our study. In only a mi-
nority of cases (12%) were the subjects informed about
the possible risks of receiving the placebo. In the study
of Bishop et al. [9], possible adverse effects related to the
use of placebo were mentioned in 49% of the informa-
tion documents. Bishop and colleagues concluded that
the information documents they examined encouraged
participants to focus on the target treatment. The use of
placebo does not automatically imply that the subjects
remain without any treatment. As in the series of studies
surveyed here, in most trials the participants continued
to receive standard care, with the study drug added
to the existing treatment. It is possible that subjects
receiving placebo may, however, experience a sub-optimal
response to their concurrent medication.
The limitations of our study include its small sample
size. Furthermore, the studies analysed involve mainly
trials related to psychiatric and neurological disorders,
while diabetes, cancer, and cardiovascular disorders repre-
sented only a minority. On the other hand, we were able
to survey all the studies submitted for ethics committee
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of only one previous study analysing how placebo had
been described in clinical trials’ participant-information
documents [9]. In that survey, most of the studies analysed
were non-commercial, whereas nearly all the studies in
our sample were sponsored by a pharmaceutical company.
In addition to participant-information documents, we
were able to analyse the study protocols and investigator
statements.
Conclusions
Ethicists have proposed that RECs should demand that
sponsors and investigators justify the use of placebo con-
trols in all studies, especially whenever the study may in-
volve withdrawal or withholding of proven effective
therapy [8]. Furthermore, RECs should approve studies
only when sufficient information has been provided for a
solid judgement about the acceptability or undesirability
of a placebo control. Furthermore, it has been stated that
patients should participate in such studies if they have
given fully informed consent, in awareness of the ran-
dom allocation, the double-blind conditions, and the use
of placebo [26]. As is discussed above, subjects asked to
participate in clinical trials may not have an appropriate
understanding of the study methods and procedures or
of the possible harm as opposed to simply the possible
benefits. It is known that patients may underestimate
the risks and discomfort of participation in clinical trials
[21]. Our study shows that, at least with respect to the
written information, the documents provided have many
shortcomings in their description of issues important
for ensuring real informed consent. We agree with the
conclusions of Bishop et al. [9] that there is a clear
ethical need for greater transparency and more respect
for the participants in the provision of written infor-
mation about placebos.
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